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Small  bowel  adenocarcinomas  are  rare  tumours,  but their  incidence  is increasing.  Their most  common
primary  location  is  the duodenum.  The  few  studies  that  have  collected  data  regarding  small  bowel  ade-
nocarcinoma  are not  homogeneous  and are  widely  spread  over  time.  Even  though  these  tumours  are
most  often  sporadic,  some  predisposing  diseases  have  been  identiﬁed,  among  which  Crohn’s  disease  and
genetic  syndromes.  Early  diagnosis  of  small  bowel  adenocarcinoma  remains  difﬁcult  despite  signiﬁcantey words:
arcinogenesis
hemotherapy
ynch syndrome
rognostic factor
are  tumour
mall intestine adenocarcinoma
radiological  and endoscopic  progress.  After surgical  resection  the  main  prognostic  factor  is  node  inva-
sion;  in  this  case,  adjuvant  chemotherapy  can  be  expected  to be  beneﬁcial,  although  this  has  not  been
established  by  randomised  trials.  For  metastatic  disease,  platinum-based  chemotherapy  seems  to  be  the
most  effective  treatment.  Targeted  therapies  have  not  yet been  evaluated  in this  type  of  cancer.
© 2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica
 Italiana S.r.l. Open access under CC BY-NC-ND license.. Epidemiology
.1. Incidence
Despite the fact that the small intestine makes up 75% of
he length of the digestive tract and 90% of its mucosal sur-
ace area, small bowel cancer is rare, accounting for less than
% of gastrointestinal cancers [1]. According to the United States
ational Cancer Database, the incidence of all small bowel can-
ers in the USA rose from 11.8 cases/million persons in 1973 to
2.7 cases/million persons in 2004 [2]. Similarly, in France, their
∗ Corresponding author at: Service de Gastroentérologie et Cancérologie Diges-
ive,  Hôpital Avicenne, HUPSSD, APHP, 125 rue de Stalingrad, 93000 Bobigny, France.
el.: +33 1 48 95 54 31; fax: +33 1 48 95 54 39.
E-mail address: thomas.aparicio@avc.aphp.fr (T. Aparicio).
590-8658 ©   2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroent
ttp://dx.doi.org/10.1016/j.dld.2013.04.013incidence also rose over the 1976–2001 period [3]. Four histological
types of cancer predominate in the small bowel: adenocarcinomas,
neuroendocrine tumours, gastrointestinal stromal tumours and
lymphomas.
Small bowel adenocarcinoma (SBA) accounts for around 40%
of all cancers of the small bowel [2–4]; similarly, neuroendocrine
tumours have roughly the same incidence. In the USA, the inci-
dence of SBA has been estimated to be of 5300 new cases, with
around 1100 deaths per year [5]. The median age at diagnosis
is in the sixth decade of life. According to the EUROCARE data,
the estimated number of annual new cases of SBA in Europe is
3600 [6]. The estimated incidence rate is 5.7 cases per million
persons. In France the estimated incidence of SBA for the period
1989–2001 was 0.31/100,000 for men  and 0.23/100,000 for women.
According to the data from the Burgundy cancer registry, the
number of new cases in France can be estimated to be 200 per
year [3].The  duodenum is the most frequently involved segment, with
55–82% of cases, followed by the jejunum (11–25%) and ileum
(7–17%) [2,3,7–10]. The increasing incidence of SBA is mainly due
to the increase in duodenal tumours [11].
erologica Italiana S.r.l. Open access under CC BY-NC-ND license.
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. Etiopathogenetic factors
.1. Environmental factors
In  contrast to colorectal cancer, studies on the pathogenesis of
BA are constrained by the rarity of the disease. Alcohol consump-
ion [12] and smoking [13] have been associated with an increased
isk of SBA. Other studies have reported an increased risk of SBA
mong the highest consumers of sugar, reﬁned carbohydrates, red
eat or smoked food, while a reduced risk was observed with
igher intakes of coffee, ﬁsh, fruit, and vegetables [14,15].
The  marked difference between the incidences of SBA and colo-
ectal adenocarcinoma suggests different exposures to carcinogens.
n the small bowel, the contact time between intestinal cells and
enobiotics or dietary carcinogens is shorter than in the colon,
wing to the shorter transit time. In addition, the proximal small
ntestine contains low concentrations of aerophilic Gram-positive
acteria. The density of the microbiota increases in the distal ileum,
ut is still much lower than in the colon, where the microbiota
roduces xenobiotic transformation during which bile salts are
econjugated and dehydroxylated to form desoxycholic acid, which
s a potential tumour promoter [16]. Moreover, the epithelial cells
f the small bowel are equipped with a wide range of microsomal
nzymes, including the benzopyrene hydroxylase, that may  protect
hem against food-derived carcinogens [17]. Nevertheless, there
s no clear explanation for the differing cancer incidences in the
uodenum and jejuno-ileum.
.2.  Carcinogenesis in SBA
The biology of SBA has been investigated only in a small number
f patients. The main genes involved in colorectal carcinogenesis
ave been studied also in SBA (Table 1).
The adenomatous polyposis coli (APC) gene has acquired a trun-
ated mutation in up to 80% of sporadic colorectal cancers, resulting
n a loss of regulation of -CATENIN that accumulates in the nucleus
s a result. This mutation is considered to be one of the main trigger-
ng events in colorectal carcinogenesis. The prevalence of the APC
ene mutation in SBA was  reported to be rather low: 0/21 [18],
/15 (8%) [19] and 3/17 (18%) [20]. These data suggest that the
arcinogenesis of SBA differs from colorectal carcinogenesis. Nev-
rtheless, several studies have reported the nuclear accumulation
f -CATENIN, most probably due to a gain-of-function mutation in
he ˇ-CATENIN gene rather than a loss of regulation due to the APC
utation. Abnormal nuclear expression of -CATENIN was found
n variable proportions of the cases analysed: 10/21 (48%) [18],
2/61 (20%) [21] and 10/20 (50%) [22]. In another study [28], large
eletions and insertions in the ˇ-CATENIN gene, resulting in sta-
ilisation of the aberrant -CATENIN, were found exclusively in
icrosatellite stable carcinomas.
Other abnormal protein expressions have been reported in SBA.
educed membrane expression of E-CADHERIN was  found in 8/21
38%) cases of SBA [18]. Overexpression of the p53 protein was
etected in the nuclei of 5/21 (24%) [18], 4/15 (27%) [19], 26/62
42%) [21], and 14/27 (52%) [23] tumours in different series of
BA cases. A loss of SMAD4 expression was found in 5/27 (18%)
ases [23]. Moreover, abnormal expression of the vascular endothe-
ial growth factor-A (VEGF-A) and the epidermal growth factor
eceptor (EGFR) was found in 50/54 (92%) and 36/54 (66%) cases,
espectively, suggesting that this type of cancer could beneﬁt from
 treatment targeting the EGFR and VEGF pathways [24]. A KRAS
utation has been described in 12/21 (57%) [25] and 21/49 (43%)
f cases [21]. A speciﬁc study of 78 duodenal tumours found a
RAS mutation in 34% of the cases [26]. HER2 expression has been
ssessed by immunohistochemistry in 2 studies: in the study of
verman et al., only one out of 54 (1.7%) tumours expressed HER2er Disease 46 (2014) 97– 104
[24].  Similarly, in the AGEO study, HER2 expression was observed
in 2/51 (3.9%) cases, in both cases in the ileum [21].
Inactivation of the DNA mismatch repair (MMR)  gene was  found
in around 15% of colorectal cancers [27]. A deﬁcient MMR  (dMMR)
can be caused either by a germline mutation of one of the 4 MMR
genes (usually MSH2 or MLH1, and more rarely MSH6 or PMS2) in
the case of Lynch syndrome, or by hypermethylation of the MLH1
promoter in sporadic tumours, especially those occurring in elderly
patients [28]. In SBA, the frequency of the dMMR phenotype is vari-
able, ranging from 5% to 35% of cases. Sporadic MMR  deﬁciency
was found in only 1/21 (≈5%) cases of SBA [18]. In another series
of 89 SBA patients, the frequency of the dMMR  phenotype was
16/89 (≈18%). In this latter study, immunohistochemistry revealed
a loss of expression of MLH1 in 7/16 dMMR  tumours. Amongst the
patients under 60 years of age, the dMMR  phenotype was  found in
10/43 (23%) and loss of expression of the MLH1 and MSH2 proteins
was observed with the same frequency [29]. Also, in this study the
frequency of dMMR  appeared to be greater in SBA than in colo-
rectal cancer, as well as being higher in young patients, suggesting
that dMMR  is more often due to Lynch syndrome in SBA than in
colorectal carcinoma. In another series of 54 SBA patients, a loss of
expression of one of the MMR  proteins occurred in 35% of patients.
Loss of MSH2, MSH6, PMS2 and MLH1 was observed in 6%, 11%, 24%
and 26% of patients, respectively. Loss of the MMR  protein gen-
erally followed 2 patterns: the loss of the combination of either
MSH2 and MSH6 (when the MSH2 gene was  affected) or PMS2
and MLH1 (when the MLH1 gene was affected) [24]. In the AGEO
study, a dMMR  phenotype was observed in 14/61 patients (23%),
mainly due to a loss of MLH1 expression [21]. In this latter study,
a trend towards a more frequent dMMR  phenotype was  observed
more often in duodenal (9/32) or jejunal (5/18) tumours than in
ileal tumours (0/13) (p = 0.07). The characterisation of SBA accord-
ing to genetic and epigenetic alterations was performed in a series
of 37 tumours [30]. A chromosomal instability (CIN) was detected
in 22/37 tumours (59%). A high level of DNA methylation was
found in 16% of the CIN tumours, in 44% of microsatellite instable
(MSI) tumours and in 44% of microsatellite and chromosomal-
stable (MACS) tumours. A KRAS mutation was observed in 55% of
CIN tumours, 0% of MSI  tumours and 10% of MACS tumours. A BRAF
mutation was detected in 6% of CIN tumours, 22% of MSI  tumours
and 22% of MACS tumours. These ﬁndings suggest that SBA and
colorectal cancer could belong to different molecular subgroups
[30].
Taken together, these ﬁndings suggest the existence of some
common carcinogenesis pathways shared between SBA and colo-
rectal carcinogenesis. Nevertheless, the APC mutation is less often
observed in SBA than in colorectal cancer, even though the Wnt
pathway is involved through ˇ-CATENIN alteration. Moreover, the
frequency of the dMMR  phenotype appears to differ in the different
SBA series, but it is generally slightly more frequent than in colorec-
tal cancer. Nevertheless, a bias towards an over-representation of
Lynch syndrome patients could be suspected in tertiary care series.
Only a large study based on an unselected cohort will allow for the
assessment of the frequencies of the various biological alterations
involved in SBA carcinogenesis.
2.3.  Genetic predisposition
2.3.1.  Familial adenomatous polyposis (FAP)
FAP is a consequence of a germinal mutation of the APC gene.
FAP patients are exposed to a very high incidence of colorectal can-
cer at a young age, and SBA is the second most common primary
cancer location. In a pooled registry study of 1255 patients with
FAP, 57 (4.5%) had an upper digestive tract adenocarcinoma. The
primary location was  the duodenum in 29 cases (50%), the ampulla
of Vater in 10 (18%), the stomach in 7 (12%), the jejunum in 5 (8.5%),
T. Aparicio et al. / Digestive and Liver Disease 46 (2014) 97– 104 99
Table  1
Molecular changes in small bowel adenocarcinoma.
Reference Number of
patients
Abnormal P53 Abnormal
-CATENIN
HER2 over-
expression
APC mutation KRAS mutation dMMR phenotype
Wheeler et al. [18] 21 24% 48% – 0% – 5%
Arai  et al. [19] 15 27% – – 8% 53% –
Blaker  et al. [20] 17 – – – 18% – 12%
Aparicio  et al. [21] 63 42% 20% 3.9% – 43% 14%
Svrcek  et al. [23] 27 52% 7.4% – – – 7%
1.7
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Blaker  et al. [25] 21 – 24% 
Planck  et al. [29] 89 – – 
nd the ileum in 1 case (1.7%) [31]. In another study, the relative
isks for duodenal adenocarcinoma or ampulloma in a FAP patient
ompared to those in the general population were 330 (95% CI,
32–681; p < 0.001), and 123 (95% CI, 33–316; p < 0.001), respec-
ively [32]. Even though the risk of duodenal adenocarcinoma in a
AP patient remained less than 5%, this cancer is nevertheless the
ain cause of cancer-related death in patients who  have undergone
 coloproctectomy [33,34].
.3.2. Lynch syndrome
Lynch  syndrome is caused by a germline mutation of a DNA mis-
atch repair gene, which exposes the patient to various types of
eoplasia, such as colorectal and endometrial cancers; he less fre-
uently ovarian, urothelial, gastric, biliary tract cancers and SBA.
arious levels of increased risk for SBA have been reported for
atients with Lynch syndrome. According to data from a Dutch
tudy, the relative risk of SBA for a patient with Lynch syndrome
as been estimated to range from 25 in the early phases of the
yndrome [35] to 291 (95% CI, 71–681) in case of an MLH1 muta-
ion and 103 (95% CI, 14–729) in case of an MSH2 mutation [36].
evertheless, the lifetime cumulative risk remains low: 0.6% and
% according to Finnish and French registries, respectively [37,38].
o far, it has not been recommended to screen Lynch syndrome
atients for SBA. However, analysis of the MMR  phenotype is
ystematically recommended in SBA, because it could reveal the
resence of Lynch syndrome [39,40].
.3.3. Peutz–Jeghers syndrome
The  Peutz–Jeghers syndrome is an autosomal dominant disor-
er due to the STK11 suppressor gene mutation that predisposes
o hamartomatous gastrointestinal tract polyposis. A relative risk
f 520 (95% CI, 220–1306) for SBA was observed in Peutz–Jeghers
yndrome patients [41]. The adenocarcinoma probably originates
rom the intra-epithelial neoplasia observed in the hamartomatous
esion.
.4. Other predisposing conditions
.4.1. Crohn’s disease
Crohn’s  disease induces chronic inﬂammation in every segment
f the digestive tract, and the distal ileum is the most frequently
nvolved. The chronic inﬂammation releases cytokines that inter-
ct with cell surface receptors and target genes that can promote
arcinogenesis [16]. The increased relative risk of SBA in Crohn’s
isease has been estimated in several population-based studies to
ange from 17 to 41 compared to the general population [42,43].
he SBA arises in an inﬂamed small bowel segment. In contrast
o sporadic SBA, in Crohn’s disease, this cancer appears in younger
atients (fourth decade of life), and mainly in the ileal segment. The
umulative risk is estimated to be 0.2% after 10 years of Crohn’s
isease and 2.2% after 25 years [44]. Another estimation, based
n the extensive SEER database and restricted to patients over 65
ears old, identiﬁed 923 cases of small bowel cancer and 142,273% – – 35%
10% 57% –
– – 18%
controls,  and conﬁrmed the increased risk of SBA in Crohn’s disease
(OR = 12.07; 95% CI, 6.07–20.80; p < 0.001). In this study, the preva-
lence of Crohn’s disease in patients with small bowel cancer was
low (1.6%); nevertheless many cases of SBA could have been missed
in the SEER database as the median age of onset of SBA in Crohn’s
disease patients is less than 65 years [45]. Another study suggests
that patients who  have undergone a small bowel resection or pro-
longed treatment with salicylate have a lower risk of developing
SBA [46].
2.4.2. Coeliac disease
Coeliac  disease is characterised by a lymphocytic inﬁltrate that
induces immunological disruption and damage to the epithelial
cells that can include premalignant changes, and could increase
the risk of both SBA and small bowel lymphoma. A cohort of 235
patients with coeliac disease showed an 8% prevalence of SBA [47].
In a British survey study that included 395 cases of small bowel can-
cer (107 lymphomas, 175 SBAs and 79 neuroendocrine tumours),
coeliac disease was found in 13% of cases of SBA and 39% of cases
of lymphoma; primary location of SBA was usually jejunal [48]. In
a Swedish registry study, the relative risk of SBA in patients with
coeliac disease versus the general population was estimated to be
10 [49].
The preliminary results of the French NADEGE cohort that
prospectively included 127 patients with SBA from March 2009 to
September 2010, revealed a genetic syndrome or a predisposing
disease in 20% of the patients: Crohn’s disease (8.6%), FAP (3%),
Lynch syndrome (3%), coeliac disease (1.5%) and Peutz–Jeghers
syndrome (0.8%) (7). These preliminary results indicate that a
predisposing disease or genetic syndrome is considerably more
frequent in SBA than in colorectal cancer.
3. Diagnosis
3.1. Clinical presentation
The  clinical presentation and diagnosis of SBA is usually delayed.
The symptoms are initially rather non-speciﬁc. In a single-centre
study of 217 patients with SBA, 66% of the patients had abdominal
pain when diagnosed. SBA was  usually diagnosed in the context
of an emergency involving an occlusion (40%) or bleeding (24%).
Bowel obstruction was mainly observed in cases of jejunal and
ileal tumour, and less frequently in duodenal tumours (47% vs 34%;
p = 0.06) [8]. In this study, diagnoses in the more recent period
(after 1988) were obtained by upper gastrointestinal endoscopy
(28%), surgery (26%), small bowel barium transit (22%), CT scan
(18%), ultrasound (3%) or physical examination (3%). The diag-
nosis was mainly obtained at advanced stages, when 35% of the
patients had synchronous metastases and 39% had tumours with
lymph-node invasion [8]. A similar stage distribution was found
in another study of 129 tumours in which 38% of the patients had
synchronous metastases and 38% had lymph-node invasion [50]. In
1 nd Liver Disease 46 (2014) 97– 104
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Table 2
TNM  classiﬁcation of small intestine adenocarcinomas.
Primary tumour (T)
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis  Carcinoma in situ
T1  Tumour invades the lamina propria,
muscularis mucosa or submucosa.
T1a  Tumour invades the lamina propria or
muscularis mucosa
T1b  Tumour invades the submucosa
T2  Tumour invades the muscularis propria
T3 Tumour invades 2 cm or less into the
subserosa or into the
non-peritonealized perimuscular
tissue (mesentery or
retroperitoneuma)
T4 Tumour perforates the visceral
peritoneum or directly invades other
organs or structures, including:
– other loops of the small intestine,
mesentery or retroperitoneum by
more than 2 cm
– through the serosa into the
abdominal wall
–  the pancreas (only for tumours in the
duodenum)
Regional lymph nodes (N)
Nx  Regional lymph nodes cannot be
assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–3 regional lymph
nodes
N2 Metastasis in 4 or more regional lymph
nodes
Distant metastasis (M)
M0  No distant metastasis
M1  Distant metastasis
From Sobin et al. [82].
rate increased non-signiﬁcantly in stage I (73.2% vs 55.6%, NS) and
signiﬁcantly in stage II (61.8% vs 32.9%, p < 0.001). Multivariate anal-
ysis identiﬁed advanced age, advanced stage, ileal location, the
recovery of <10 lymph nodes, and the number of positive nodes as
Table 3
Tumour stages of small intestine adenocarcinoma.
Stage T N M
0 Tis N0 M0
1 T1, T2 N0 M0
2A T3 N0 M0
2B T4 N0 M0
3A Any T N1 M000 T. Aparicio et al. / Digestive a
rohn’s disease, the diagnosis is mainly obtained postoperatively
fter resection of an obstructed small bowel segment [44].
.2.  Diagnosis
For  SBA, small bowel barium transit has a sensitivity of about
0% [51], and CT scans have an overall accuracy rate of 47% [52,53].
t should be pointed out that in a context of obscure bleeding after
pper and lower endoscopy, a small bowel investigation should
ystematically be done. New investigation tools, such as CT entero-
lysis, MR  enteroclysis, capsule endoscopy, and enteroscopy now
llow for an extensive exploration of small bowel and should thus
ake early diagnosis possible. CT enteroclysis has a sensitivity of
5–95% for the diagnosis of small bowel tumour, and a speciﬁcity of
0–96% [51,54]. A study including 150 patients who were clinically
uspected of having a small-bowel neoplasm, and whose previous
pper and lower gastrointestinal endoscopy ﬁndings were normal,
nderwent MR  enteroclysis. The overall sensitivity, speciﬁcity, and
ccuracy in identifying patients with small bowel lesions were 86%
19 of 22), 98% (126 of 128), and 97% (145 of 150), respectively. Two
R enteroclysis examinations yielded false-positive ﬁndings, and
 yielded false-negative ﬁndings [55].
Capsule endoscopy allows carrying out a complete small bowel
xploration as an outpatient procedure, however it should not be
erformed in a context of sub-occlusion. When it is performed to
xplore obscure bleeding, the sensitivity for diagnosing a small
owel tumour is between 88.9% and 95% and its speciﬁcity 75–95%
56,57]. Double balloon enteroscopy can be used for a wide range
f small bowel investigations. Nevertheless, this procedure is less
onvenient than capsule endoscopy, and should be used only if a
iopsy or preoperative tattoo are required [58]. In some cases, how-
ver, enteroscopy can diagnose a small bowel tumour missed by
ideocapsule endoscopy [59].
.3. Other recommended investigations after SBA diagnosis
The  French guidelines (www.tncd.org, last updated in 2013)
ecommend  performing a thoraco-abdomino-pelvic CT scan to
ssess distant metastases, and an upper and lower gastrointesti-
al endoscopy to look for other tumours suggesting a predisposing
enetic disease. A baseline plasmatic carcinoembryonic antigen
CEA) and carbohydrate antigen (CA) 19.9 assay should be done,
specially in cases of advanced disease, since the levels of these
arkers are of prognostic value [60].
In a context of a predisposing genetic disease or Crohn’s dis-
ase, a full small bowel exploration should be performed (with
nteroscanner or capsule endoscopy if there is no small bowel
tenosis) to detect synchronous tumours.
An assay of anti-transglutaminase A antibodies and a duodenal
iopsy are recommended to detect coeliac disease.
Two different tests can be used to detect Lynch syndrome: the
rst identiﬁes microsatellite instability by testing 5 microsatel-
ite loci, and the second conﬁrms the lack of expression of 1 or 2
ismatch repair proteins by means of immunohistochemical tech-
iques.
. Prognosis
SBA carries a poor prognosis at all stages, with a 5-year overall
urvival (OS) rate ranging from 14% to 33% [2,3,6,8,10]. The 5-year
S is correlated to the tumour stage (Tables 2 and 3): 50–60% for
tage I (incidence from 4% to 12%), 39–55% for stage II (incidence
rom 14% to 30%), 10–40% for stage III (incidence from 19% to 27%)
nd 3–5% for stage IV (incidence from 32% to 46%) [7–10,50,61]. SBA
rognosis appears to be intermediate between those of colon and
astric cancers, and surgery for complete resection (R0) remains thea Note: The non-peritonealized perimuscular tissue for the jejunum and ileum is
part of the mesentery. For the duodenum, it is part of the retroperitoneum in areas
where there is no serosa.
only potentially curative treatment [50]. The frequency of locally-
advanced unresectable cancer is not reported in most of the studies,
however, in the preliminary report of the NADEGE cohort, a locally-
advanced cancer occurred in 5% of the cases [7].
Lymph-node invasion is the main prognostic factor for local
SBA [8,50]; moreover, the number of lymph nodes assessed and
the number of positive lymph nodes are of prognostic value. In
stage III patients, a positive number of invaded lymph nodes ≥3
had a worse 5-year disease-free survival (DFS) rate than patients
with 1–2 invaded lymph nodes (37% vs 57%) [62]. For jejuno-ileal
tumours, when 10 or more lymph nodes were examined, the OS3B Any T N2 M0
4 Any T Any M M1
From Sobin et al. [82].
T, tumour; N, nodes; M, metastases; Tis, in situ.
nd Liver Disease 46 (2014) 97– 104 101
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igniﬁcant predictors of poor OS [63]. Thus, a curative resection
t an early stage (stages I and II) should systematically include a
egional lymphadenectomy.
Several  studies suggest that a duodenal primary tumour has a
orse prognosis than a jejunal or ileal primary tumour [8,9,62].
ther factors for poor prognosis have also been reported: advanced
ge, pT4 tumour stage, poorly differentiated tumour, positive
esection margins, lymphovascular invasion and a lymph node ratio
f ≥10% [9,64,65]. One study has reported 12/74 (16%) second can-
ers after a curative resection, 5 of which could have corresponded
o Lynch syndrome. This high frequency of second cancers justiﬁes
 prolonged follow-up after SBA treatment [66].
In metastatic or locally-advanced SBA treated with chemother-
py, a retrospective study found that impaired WHO  performance
tatus and an above-normal value of CEA or CA 19.9 were prognostic
actors for poor survival [60].
. Treatment
.1. Localised cancer
Complete  resection (R0) of the primary tumour with loco-
egional lymph node resection is mandatory. In the context of
osterior invasion, pre-operative treatment should be considered,
nd resection reconsidered after 2–3 months of chemotherapy.
In  the context of unresectable metastases, primary tumour
esection is not recommended except in an emergency such
s bowel obstruction, perforation or uncontrolled bleeding. If a
ultidisciplinary evaluation concludes that the metastases are
esectable, resection of the metastases can consist of either 1 or 2
urgical procedures, possibly with chemotherapy during the inter-
al between the procedures. However, more data are required to
valuate the value of metastasis resection in SBA.
For duodenal tumours, a Whipple resection should be per-
ormed [8] for a tumour in the second segment of the duodenum
r for an inﬁltrating tumour in the proximal or distal duodenum.
dditionally, resection of the peri-duodenal, peri-pancreatic, and
epatic lymph nodes should also be performed, as well as resection
f the right side of the coeliac and superior mesenteric arteries. A
uodenal resection alone could be performed for a proximal duo-
enal tumour or a distal duodenal tumour with no inﬁltration of
djacent organs [67], despite the fact that this procedure is associ-
ted with poor prognosis [68]. An R0 resection is to be preferred,
s R1 or R2 resections are strongly associated with poor prognosis
69].
For jejunal and ileal tumours, an R0 resection with lymph node
esection and jejuno-jejunal or ileo-ileal anastomosis should be
erformed. If the last ileal loop or Bauhin’s valve are involved, an
leocoecal or right hemicolectomy should be performed with liga-
ion of the ileocolic artery so as to allow for lymph node resection.
To date, no standard adjuvant regimen has been deﬁned due
o the lack of randomised controlled trials. The only data available
re those from retrospectives studies. The inability to control for
he various prognostic factors inﬂuencing the original decision to
dminister adjuvant therapy has been a major limitation of ret-
ospective studies, as the patients who receive adjuvant therapy
end to be those at greater risk of disease recurrence on basis of the
urrently-used prognostic factors.
In a review of the US National Cancer Database, 11% of patients
eceived radiotherapy with or without chemotherapy mainly for
uodenal primary tumours [9]. Nevertheless, in a retrospective
tudy of 48 duodenal adenocarcinomas resected with a curative
ntent, chemoradiotherapy did not improve survival [68]. The data
vailable do not establish a clear recommendation for radiotherapy
n R1 or R2 resection or locally-advanced duodenal cancer.Fig. 1. Treatment for localised small bowel adenocarcinoma after an R0 resection
according  to the 2013 French guidelines (www.tncd.org).
Several retrospective studies have found no beneﬁt in adjuvant
chemotherapy after potentially curative surgical resections of SBA
[8,64,70,71]. These negative results may  be due to the small number
of patients treated, a bias in selecting patients for treatment or an
inadequate chemotherapy regimen.
In a single-centre, retrospective study including 54 patients
treated with an R0 resection between 1990 and 2008, 30 (56%)
patients received adjuvant therapy. In multivariate analysis, the
use of adjuvant therapy was found to be associated with an
improvement in the DFS (HR 0.27; 95% CI 0.07–0.98, p = 0.05), but
not in the OS (HR 0.47; 95% CI 0.13–1.62, p = 0.23). In patients
with a high risk of recurrence (deﬁned as a lymph node ratio
[invaded/without metastasis] ≥10%), adjuvant therapy appeared to
improve OS (p = 0.04), but not DFS (p = 0.15) [65]. Despite the lack
of evidence supporting the delivery of adjuvant chemotherapy for
SBA, an analysis in the USA of the National Cancer Database has
shown an increase in the use of chemotherapy from 8% in 1985 to
24% in 2005 [2].
The  reported efﬁcacy of ﬂuoropyrimidine and oxaliplatin in
advanced SBA [60,72], and the efﬁcacy of the same regimen in
the adjuvant chemotherapy of CRC have led to the French recom-
mendation of an adjuvant ﬂuoropyrimidine and oxaliplatin-based
chemotherapy after a curative R0 resection of a stage-III SBA
(www.tncd.org, last updated in 2013). For stage-II tumours, adju-
vant chemotherapy is optional for pT4. Nevertheless, given the
cumulative evidence of poor prognosis for poorly-differentiated
tumours with a resected lymph node number <10, adjuvant
chemotherapy should be discussed in such cases (Fig. 1).
A  prospective international phase-III study (the BALAD study),
promoted by the International Rare Cancer Initiative, comparing
observation to adjuvant chemotherapy after R0 resection of SBA
should begin soon.
5.2.  Metastatic SBA
Very  few studies have been published on the type of chemother-
apy used for advanced SBA (Table 4). Most of the studies available
are small, retrospective or involve old chemotherapy regimens.
Overall, they report a median OS of 8–18 months and objective
response rates (ORR) ranging from 5% to 37% [73–78]. Several
retrospective studies suggest that chemotherapy prolongs OS in
patients with advanced SBA [8,74,75], but there is no agreed
frontline regimen owing to the lack of randomised trials. A ret-
rospective comparison of OS, according to whether palliative
chemotherapy was prescribed, showed a signiﬁcant increase of
survival in treated patient (12 months vs 2 months, p = 0.02) [8].
In another series from the registry of British Columbia, patients
who received chemotherapy (n = 16) had an OS of 15.6 months,
while patients who  did not (n = 21) had an OS of 7.7 months [74].
Only few studies compared a speciﬁc regimen of chemotherapy to
other protocols. A retrospective study of 44 patients suggests that
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Table  4
Studies evaluating chemotherapy in advanced small bowel adenocarcinoma.
Reference Regimen Number of patients Response rate (%) Progression
free survival
(months)
Overall survival
(months)
Crawley et al. [73] 5FU 8 37 7.8 13.0
Locher  et al. [78] 5FU + cisplatin 20 21 8.0 14.0
Gibson  et al. [76] 5FU + doxorubicin + MMC  38 18 5.0 8.0
Zaanan  et al. [60] FOLFOX 48 34 6.9 17.8
LV5FU2 10 0 7.7 13.5
LV5FU2 + cisplatin 19 30 6.0 9.6
FOLFIRI 16 9 4.8 10.6
Overman  et al. [79] 5FU + cisplatin 29 41 8.7 14.8
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F5FU without cisplatin 41 
Overman  et al. [72] Capecitabine + oxaliplatin 30 
Zaanan  et al. [81] FOLFIRI (second line) 28 
emcitabine and irinotecan-based chemotherapy gives better
esults than 5FU monotherapy [75]. A retrospective, single-centre
tudy of 80 patients with metastatic SBA suggested that platinum-
ased chemotherapy gave a higher ORR than other chemotherapy
egimens (46% vs 16%; p = 0.01) and longer median progression-free
urvival (PFS) (8.7 vs 3.9 months; p ≤ 0.01), although the median
S was not signiﬁcantly different (14.8 vs 12.0 months; p = 0.10)
79]. However, this study did not address the respective risk-beneﬁt
atios of the different platinum salts (cisplatin, oxaliplatin, etc.),
ven though the clinical efﬁcacy and antitumour mechanisms of
hese drugs are very different [80]. A prospective phase-II trial
f capecitabine plus oxaliplatin has given interesting results in
atients with advanced small-bowel and ampullary adenocarci-
omas, with an ORR of 50%, a median time to progression of
1.3 months, and a median OS of 20.4 months [72]. Another ret-
ospective multicentre study evaluated LV5FU2 (n = 10), FOLFOX
n = 48), FOLFIRI (n = 19) and LV5FU2-cisplatin (n = 16) in 93 con-
ecutive patients. The median PFS times in patients treated with
V5FU2, FOLFOX, FOLFIRI and LV5FU2-cisplatin were 7.7, 6.9, 6.0
nd 4.8 months, respectively, while the median OS times were
3.5, 17.8, 10.6 and 9.3 months, respectively. In a multivariate anal-
sis, the WHO  performance status (p < 0.0001) and the elevated
EA (p = 0.02) and CA 19.9 (p = 0.03) serum levels were the only
ariables signiﬁcantly associated with poor OS. In the subgroup of
atients treated with platinum-based chemotherapy, multivariate
nalysis showed that LV5FU2-cisplatin was associated with poorer
FS (p < 0.0001) and OS (p = 0.02) than FOLFOX [60]. From the same
ig. 2. Treatment for metastatic small bowel adenocarcinoma according to the 2013
rench guidelines (www.tncd.org).
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series, the effectiveness of FOLFIRI in second-line chemotherapy
was investigated in 28 patients who  had been treated with plat-
inum salts in ﬁrst line therapy: the objective response rate was
20% and the disease control rate was 52%, while the median PFS
and OS were 3.2 and 10.5 months, respectively. This suggests that
the FOLFIRI regimen exhibits modest activity as a second-line treat-
ment in patients with advanced SBA after failure of a platinum
salt-based ﬁrst-line chemotherapy [81].
So far, no data is available for targeted therapy. The oxaliplatin-
based chemotherapy seems to be the best choice, and it is
recommended as a ﬁrst line treatment by the French guidelines
(www.tncd.org, last updated in 2013) (Fig. 2).
Overall, advanced SBA had a worse prognosis than colorectal
cancer, but a better prognosis than gastric or pancreatic cancer,
with a median OS exceeding 12 months.
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